Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis

BACKGROUND: New oral anticoagulants (NOACs) have been becoming prevalent in recent years and are increasingly used in the treatment of port vein thrombosis. The difference of the efficacy and safety between rivaroxaban and dabigatran remains unclear in the treatment of cirrhotic patients with acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Haonan, Wu, Mingdong, Yu, Shixiong, Xia, Han, Yu, Wu, Huang, Kai, Chen, Yikuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521568/
https://www.ncbi.nlm.nih.gov/pubmed/37749527
http://dx.doi.org/10.1186/s12876-023-02960-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521568/
https://www.ncbi.nlm.nih.gov/pubmed/37749527
http://dx.doi.org/10.1186/s12876-023-02960-8

Ejemplares similares